Atbin Djamshidian

Dr. Atbin Djamshidian

Department of Neurology, Medical University Innsbruck, 6020 Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2021 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
VRVerena Rass
Verena Rass
RBRonny Beer
Ronny Beer
ASAlois Josef Schiefecker
Alois Josef Schiefecker
MKMario Kofler
Mario Kofler
ALAnna Lindner
Anna Lindner
RHRaimund Helbok
Raimund Helbok
Background and purpose: To assess neurological manifestations and health‐related quality of life (QoL) 3 months after COVID‐19.Methods: In this prospective, multicenter, observational cohort study we systematically evaluated neurological signs and diseases by detailed neurological examination and a predefined test battery assessing smelling disorders (16‐item Sniffin Sticks test), cognitive deficits (Montreal Cognitive Assessment), QoL (36‐item Short Form), and mental health (Hospital Anxiety and Depression Scale, Posttraumatic Stress Disorder Checklist–5) 3 months after disease onset.Results: Of 135 consecutive COVID‐19 patients, 31 (23%) required intensive care unit (ICU) care (severe), 72 (53%) were admitted to the regular ward (moderate), and 32 (24%) underwent outpatient care (mild) during acute disease. At the 3‐month follow‐up, 20 patients (15%) presented with one or more neurological syndromes that were not evident before COVID‐19. These included polyneuro/myopathy (n = 17, 13%) with one patient presenting with Guillain‐Barré syndrome, mild encephalopathy (n = 2, 2%), parkinsonism (n = 1, 1%), orthostatic hypotension (n = 1, 1%), and ischemic stroke (n = 1, 1%). Objective testing revealed hyposmia/anosmia in 57/127 (45%) patients at the 3‐month follow‐up. Self‐reported hyposmia/anosmia was lower (17%) at 3 months, however, improved when compared to the acute disease phase (44%; p < 0.001). At follow‐up, cognitive deficits were apparent in 23%, and QoL was impaired in 31%. Assessment of mental health revealed symptoms of depression, anxiety, and posttraumatic stress disorders in 11%, 25%, and 11%, respectively.Conclusions: Despite recovery from the acute infection, neurological symptoms were prevalent at the 3‐month follow‐up. Above all, smelling disorders were persistent in a large proportion of patients.

23 March 2022 in European Journal of Neurology
Verified
Journal Article
Open access
VRVerena Rass
Verena Rass
RBRonny Beer
Ronny Beer
ASAlois Josef Schiefecker
Alois Josef Schiefecker
ALAnna Lindner
Anna Lindner
MKMario Kofler
Mario Kofler
RHRaimund Helbok
Raimund Helbok
Background and purpose: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19.Methods: A prospective, multicentre, longitudinal cohort study in COVID‐19 survivors was performed. At a 3‐month and 1‐year follow‐up, patients were assessed for neurological impairments by a neurological examination and a standardized test battery including the assessment of hyposmia (16‐item Sniffin' Sticks test), cognitive deficits (Montreal Cognitive Assessment < 26) and mental health (Hospital Anxiety and Depression Scale and Post‐traumatic Stress Disorder Checklist 5).Results: Eighty‐one patients were evaluated 1 year after COVID‐19, out of which 76 (94%) patients completed a 3‐month and 1‐year follow‐up. Patients were 54 (47–64) years old and 59% were male. New and persistent neurological disorders were found in 15% (3 months) and 12% (10/81; 1 year). Symptoms at 1‐year follow‐up were reported by 48/81 (59%) patients, including fatigue (38%), concentration difficulties (25%), forgetfulness (25%), sleep disturbances (22%), myalgia (17%), limb weakness (17%), headache (16%), impaired sensation (16%) and hyposmia (15%). Neurological examination revealed findings in 52/81 (64%) patients without improvement over time (3 months, 61%, p = 0.230) including objective hyposmia (Sniffin' Sticks test 0.05).Conclusion: Our data indicate that a significant patient number still suffer from neurological sequelae including neuropsychiatric symptoms 1 year after COVID‐19 calling for interdisciplinary management of these patients.

20 July 2012 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
ADAtbin Djamshidian
Atbin Djamshidian
SOSean S. O'Sullivan
Sean S. O'Sullivan
YSYanosh Sanotsky
Yanosh Sanotsky
SSStephen Sharman
Stephen Sharman
YMYuriy Matviyenko
Yuriy Matviyenko
BABruno B. Averbeck
Bruno B. Averbeck

18 August 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
ADAtbin Djamshidian
Atbin Djamshidian
AJAshwani Jha
Ashwani Jha
SOSean S. O'SUllivan
Sean S. O'SUllivan
LSLaura Silveira‐Moriyama
Laura Silveira‐Moriyama
CJClare Jacobson
Clare Jacobson
BABruno B. Averbeck
Bruno B. Averbeck

28 March 2014 in Annual Review of Clinical Psychology
Verified
Journal Article
Closed access
BAB.B. Averbeck
B.B. Averbeck
SOS.S. O'SUllivan
S.S. O'SUllivan
ADAtbin Djamshidian
Atbin Djamshidian
Impulsive-compulsive behaviors (ICBs) in Parkinson's disease (PD) are a common and devastating side effect of dopamine replacement therapy. In this review we describe the phenomenology, prevalence, and risk factors of patients with PD. Results of behavioral studies assessing the neuropsychological profile of patients with PD emphasize that the ICBs, which are behavioral addictions, are not hedonically motivated. Rather, other factors such as the inability to cope with uncertainty may be triggering ICBs. New insights from functional imaging studies, strengthening the incentive salience hypothesis, are discussed, and therapeutic guidelines for the management of ICBs in PD are given.

20 November 2013 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
ADAtbin Djamshidian
Atbin Djamshidian
ALAndrew J Lees
Andrew J Lees
In this manuscript we summarize the role of chronic stress as a potential trigger factor for Parkinson's disease. Underlying mechanisms and stress-induced changes to the neuronal networks have been highlighted. Examples of stress induced reversible symptoms that resemble parkinsonism in humans and in animal models raise the question whether emotional stress can cause striatal degeneration in susceptible patients. A Pubmed literature review searching for the terms ‘Stress’, ‘Distress and Parkinson's disease’, 'Emotional Distress and Parkinson's disease’, ‘Stress and Parkinson's disease’, ‘Prodromal Parkinson's disease’, ‘Non motor symptoms and Parkinson's disease’, ‘Paradoxical kinesia’, ‘Psychogenic parkinsonism’, ‘Functional somatic syndromes’, ‘Chronic fatigue syndrome’, ‘Irritable bowel syndrome’, ‘Fibromyalgia’, ‘Dopamine and fibromyalgia’, ‘Dopamine and chronic fatigue syndrome’ and ‘Dopamine and irritable bowel syndrome’ was carried out until April 2013. Articles were also identified through searches of the authors’ own files. Only papers published in English were reviewed. The final reference list was generated on the basis of originality and relevance to the broad scope of this viewpoint.